An interventional study of HAL spectacle lens and Single Vision spectacle lens in Myopia, sponsored by Essilor International. Completed at 7 sites in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by Essilor International · Not applicable, Interventional, and Treatment
To evaluate the visual performance of (high and low contrast distance visual acuity, reading speed, near visual acuity, and near contrast sensitivity) of HAL spectacle lenses (habitual correction) in comparison with single vision control lenses.
984 studies on the registry are indexed under Myopia; 210 are open to participants now.
This study's enrollment of 88 is close to the median of 80 across 783 interventional studies indexed under Myopia.
Browse Myopia studies →Essilor International is the lead sponsor of 38 studies on the registry; 20 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
HAL spectacle lens using a innovative spectacle lens to control myopia progression
Device: HAL spectacle lens
Single vision spectacle lens for myopia and astigmatism correction
Device: Single Vision spectacle lens
HAL spectacle lens for myopia control
Single vision spectacle lens for myopia and astigmatism correction
Reading Speed
Reading speed (mean words per minute) collected using the Wolffsohn Research iPad OptomCentral App
Time frame: Between Year 1 and Year 2 of the WS10246 study, representing an average timeframe of 1.5 years into the parent study.
Binocular distance high contrast visual acuity (VA) through the lens periphery
Measured to the nearest letter using a standard ETDRS chart at 4 meters.
Time frame: Between Year 1 and Year 2 of the WS10246 study, representing an average timeframe of 1.5 years into the parent study.
Binocular photopic near contrast sensitivity function (CSF)
Evaluated at 40 cm using the iPad OptomCentral App across various spatial frequencies to calculate the Area Under the Log Contrast Sensitivity Function (AULCSF).
Time frame: Between Year 1 and Year 2 of the WS10246 study, representing an average timeframe of 1.5 years into the parent study.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Essilor International